G92.04 Immune effector cell-associated neurotoxicity syndrome, grade 4

Name of the Condition

• Immune effector cell-associated neurotoxicity syndrome, grade 4

Summary

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological condition that can occur following treatment with certain immunotherapies, particularly those involving immune effector cells like CAR T-cells. It is characterized by a range of neurologic symptoms resulting from inflammation or toxicity to the central nervous system. The "grade 4" designation indicates severe severity, typically involving life-threatening or disabling symptoms requiring intensive medical intervention.

Causes

ICANS is caused by the release of inflammatory cytokines and immune-mediated damage to the brain and nervous system, typically triggered by immunotherapy treatments that activate immune cells to target cancer cells. The exact mechanisms involve cytokine release and potential direct neurotoxic effects.

Risk Factors

• Receipt of immunotherapy, especially CAR T-cell therapy or other immune effector cell treatments
• Underlying cancer type and disease burden
• Prior history of neurologic conditions or central nervous system involvement
• Concomitant use of other medications that may affect neurologic function

Symptoms

• Altered mental status or confusion
• Aphasia (difficulty speaking or understanding language)
• Tremors or asterixis (hand flapping)
• Seizures
• Headache
• Dizziness or ataxia (loss of coordination)
• Visual disturbances
• Coma or stupor

Diagnosis

Diagnosis is based on clinical evaluation of neurologic symptoms in the context of recent immunotherapy administration. Grading follows standardized systems (e.g., ASTCT consensus criteria) to assess severity. Laboratory tests and imaging may be used to rule out other causes, but clinical correlation is primary.

Treatment Options

Treatment focuses on managing symptoms and supporting the patient. Interventions may include corticosteroids, antiseizure medications, and supportive care. Management is often multidisciplinary, involving neurology, oncology, and critical care teams.

Prognosis and Follow-Up

Prognosis depends on the severity of symptoms and promptness of treatment. Severe cases (grade 4) may have prolonged recovery or residual deficits. Follow-up includes monitoring for symptom resolution and potential long-term neurologic effects.

Complications

• Prolonged coma or neurologic impairment
• Seizure disorders
• Cognitive dysfunction
• Respiratory failure requiring mechanical ventilation

Lifestyle & Prevention

Prevention is limited to careful patient selection and monitoring during immunotherapy. Lifestyle modifications are not typically applicable, but adherence to treatment protocols and early symptom reporting are critical.

When to Seek Professional Help

Seek immediate medical attention if symptoms such as severe confusion, seizures, or loss of consciousness occur after immunotherapy. Early intervention improves outcomes.

Tips for Medical Coders

Code G92.04 is specific to immune effector cell-associated neurotoxicity syndrome of grade 4 severity. Documentation should clearly indicate the grade and its impact on the patient. Ensure the code aligns with clinical findings and treatment context.